- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01231451
Depot Contraception With and Without Lopinavir/Ritonavir
The Pharmacokinetics of Depot Medroxyprogesterone Acetate (DMPA) in the Absence and Presence of Lopinavir/Ritonavir in HIV-1 Infected Women
DMPA (depot medroxyprogesterone acetate or the 'depot' injection) is a widely used contraception. It is popular in woman with HIV as it probably still works when you take HIV drugs. HIV drugs can increase or decrease the level of other drugs (e.g. contraceptives) in your bloodstream which may make them work less well or increase side effects. It is assumed that DMPA can be given with HIV drugs there are no studies proving this.
The purpose of the study is to investigate whether an HIV drug combination containing lopinavir/ritonavir affects DMPA when they are taken at the same time.
Study Overview
Detailed Description
Lopinavir/ritonavir (LPV/r) is licensed for use in combination with other antiretrovirals for the treatment of HIV infection. Like other agents from the protease inhibitor class, LPV/r inhibits the 3A isoenzyme of the hepatic cytochrome P450 system and may increase the levels of drugs metabolised via this route. However, LPV/r has also been shown in vivo to induce its own metabolism and to increase the biotransformation of some drugs metabolized by P450 enzymes and by glucuronidation.
Women account for an increasing proportion of the HIV epidemic in the UK. The huge reductions in HIV-related mortality and morbidity associated with the use of effective combination antiretroviral therapy have led to a shift in focus to longer term issues, including reproductive health and contraception. The impact of a variety of antiretrovirals on the plasma pharmacokinetics of oral oestrogen and progesterone preparations have been investigated and in general NNRTIs and boosted PIs cause a reduction in levels of both, particularly oral oestrogen preparations. Most package inserts for combined (oestrogen and progestogen) and progestogen-only oral contraceptives recommend that additional contraceptive methods be employed with concomitant use of enzyme-inducing agents.
Injectable contraception provides highly effective contraception without the need for daily pill taking, an important factor to consider for individuals already taking regular medication. Depot medroxyprogesterone acetate (DMPA) is the most frequently prescribed injectable method. DMPA, like other progestogens, is metabolised by the cytochrome P450 system but interaction studies in women on antiretrovirals are limited. A study of 59 women on DMPA contraception plus an unboosted PI (nelfinavir) or an NNRTI (efavirenz or nevirapine) measured DMPA levels and compared them with 16 women on either no therapy or NRTIs only (no potential for drug interaction). DMPA levels were similar in all groups and suppression of ovulation over a 12 week period was also similar in all groups.
Although the high levels of DMPA achieved over the dosing interval make any pharmacokinetic interaction unlikely to be clinically significant, some clinicians advise a reduction in the interval between DMPA injections from 12 to 10 weeks in patients on an NNRTI or boosted PI; there is no clear evidence to support this approach. Although the described study supports normal dosing intervals for women on an NNRTI, the unboosted PI nelfinavir is not recommended as standard of care and the impact of ritonavir-boosted PIs is unclear. The summary of product characteristics for DMPA advises a normal dosing interval even when using a potent enzyme inducers, suggesting no additional intervention is required when prescribing a boosted PI. Formal pharmacokinetic data is crucial to clarify this important area.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, SW10 9NH
- St Stephen's Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The ability to understand and sign a written informed consent form, prior to participation in any screening procedure and must be willing to comply with all study requirements.
- Non-pregnant, non-lactating premenopausal females.
- No current hormonal contraception (short acting methods eg oral contraceptive pills and patches can be removed at screening)
- Regular menstrual periods such that DMPA can be administered between days 1-5 of menstrual cycle
- Between 18 and 45 years, inclusive.
- Documented HIV-1 infection
- Must be willing to use a barrier method of contraception to avoid pregnancy throughout the study, and for at least 56 days following completion of the study.
- CD4 count > 200 at screening (Note: retesting of screening CD4 count allowed).
- Clinician and patient happy to delay HAART until week 12 of study
- Not currently on HAART and eligible to receive LPV/r and Truvada as determined by their primary HIV care provider in accordance with treatment guidelines
- If history of HAART exposure, no virological failure (prior drug switches allowed if for tolerability/toxicity/convenience of dosing).
- Agrees not to change regimen, outside the study recommendations, from baseline until end of the treatment period unless this is medically indicated as decided by the treating physician
Exclusion Criteria:
- Any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance with the protocol. This would include any active clinically significant renal, cardiac, hepatic, pulmonary, vascular, metabolic disorders or malignancy.
- Have a body mass index (BMI) >35
- Personal history of venous thromboembolism (VTE) or pulmonary embolism (PE)
- Presence of any current active AIDS defining illness (Category C conditions in the CDC Classification System for HIV 1993) except stable cutaneous Kaposi's Sarcoma
- Osteoporosis or significant risk factors for osteoporosis (alcohol abuse, long-term anticonvulsants/corticosteroids, BMI less than 18, eating disorder, previous low trauma fracture, significant family history osteoporosis)
Conditions for which DMPA is contra-indicated or risks outweigh benefits:
- Significant multiple risk factors for arterial cardiovascular disease
- Vascular disease
- Previous or current venous thromboembolism (VTE) or pulmonary embolism (PE)
- Ischaemic heart disease
- Stroke (history of cerebrovascular accident)
- Headaches migraine with aura, at any age
- Unexplained vaginal bleeding
- Gestational trophoblastic neoplasia (GTN) (includes hydatidiform mole, invasive mole, placental site trophoblastic tumour) hCG abnormal
- Breast cancer (past or current) or strong family history
- Diabetes nephropathy/retinopathy/neuropathy
- Other vascular disease or diabetes of >20 years' duration
- Viral hepatitis (active)
- Presence or history of any sever hepatic disease where liver function tests have not returned to normal
- Cirrhosis (decompensated)
- Clinically relevant alcohol or drug use (positive urine drug screen, excluding cannabinoids) or history of alcohol or drug use considered by the Investigator to be sufficient to hinder compliance, follow-up procedures or evaluation of adverse events. Smoking is permitted, but tobacco intake should remain consistent throughout the study.
- The use of disallowed concomitant therapy (See section 5.2).
- Previous allergy to any of the constituents of the study pharmaceuticals.
- Exposure to any investigational drug or placebo within 4 weeks of baseline.
- Any HAART exposure within 6 months of screening for this study (ie participants need to be treatment-naïve or on a treatment interruption for 6 months or more).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: All Subjects
All Subjects will receive the same intervention
|
All subjects will take DMPA
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pharmacokinetics of depot medroxyprogesterone acetate (DMPA)
Time Frame: week 1 - week 24
|
To investigate the pharmacokinetics of depot medroxyprogesterone acetate (DMPA) in the absence and presence of lopinavir/ritonavir in HIV- 1 infected women |
week 1 - week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of co-administration of DMPA and lopinavir/ritonavir
Time Frame: Week 1 - week 24
|
To investigate the impact of co-administration of DMPA and lopinavir/ritonavir on surrogate markers of contraceptive efficacy (LH, FSH, oestradiol)
|
Week 1 - week 24
|
Safety of DMPA
Time Frame: Week 1 - week 24
|
To investigate the safety of DMPA in HIV infected women on lopinavir/ritonavir
|
Week 1 - week 24
|
Impact of DMPA on lopinavir/ritonavir plasma concentrations
Time Frame: week 1 - week 24
|
To investigate the impact of DMPA on lopinavir/ritonavir plasma concentrations compared with historical controls
|
week 1 - week 24
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SSAT 038
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infection
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Beckman Coulter, Inc.CompletedHIV I Infection | HIV-2 InfectionFrance
-
Allegheny Singer Research Institute (also known...Active, not recruitingHIV Infections | HIV-1-infection | HIV I InfectionUnited States
-
Erasmus Medical CenterRecruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
Rockefeller UniversityCompletedHIV Infection | Healthy Volunteers | HIV-1 InfectionUnited States
-
AIDS Healthcare FoundationUniversity of California, Los AngelesCompleted
-
Erasmus Medical CenterActive, not recruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
Merck Sharp & Dohme LLCCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal AntibodyUnited States
Clinical Trials on DMPA
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHypoestrogenism | Bone Demineralization | Subclinical Kidney Injury | Bone MicroarchitectureUganda
-
FHI 360United States Agency for International Development (USAID); Aga Khan University and other collaboratorsCompleted
-
King Chulalongkorn Memorial HospitalCompleted
-
University of California, BerkeleyTigray Regional Health Bureau; Venture Strategies for Health and Development; Venture Strategies innovationsCompletedContraception | Family Planning | Task Shifting | Community Based Distribution | DMPAEthiopia
-
FHI 360Oregon Health and Science University; Asociación Dominicana Pro Bienestar de...CompletedContraceptionUnited States, Dominican Republic
-
AbbVieCompleted
-
University of PennsylvaniaCompleted
-
Oregon Health and Science UniversityRecruiting
-
Boston UniversityFamily Planning FellowshipCompletedAbortion; InducedUnited States
-
University of PittsburghUniversity of ZimbabweCompletedHIV | Contraception | Microbiota | Immune Cells (Mucosal and Systemic)Zimbabwe